we conclude that , because of protocol violations , small sample size , and the number of patients lost to follow-up , this study was unable to determine what effect use of doxorubicin as adjuvant therapy had on recurrence , progression , and survival of the endometrial cancer study population .
C0013089
doxorubicin
C0062074
had